The European Medicines Agency has issued a draft strategy for regulatory science and is seeking feedback from national authorities, researchers, industry and the public.
The draft strategy, published on 19 December, covers both human and veterinary regulation and looks ahead to 2025. The agency uses regulatory science, which covers basic and applied biomedical and social science activities, to ensure that medical products and processes are safe and effective.
“The pace of innovation has accelerated dramatically in recent years and regulators need to be ready to support the development of increasingly complex medicines,” the agency’s executive director Guido Rasi said in his foreword. “The launch of this stakeholder consultation provides an opportunity for you to help shape the agency’s regulatory science strategy and decide where the future priorities and resources should be attributed.”